Genentech inks $650M deal with protein degradation pioneer Arvinas
Genentech is doubling down on its commitment to New Haven biotech Arvinas, extending the duo’s partnership and tacking an additional $350 million onto the total deal value.
The companies have been working together since 2015, with Genentech licensing Arvinas’ platform for protein degradation to do some secretive R&D. Back then, Genentech wasn’t disclosing its disease targets, and it still isn’t. They’re only telling us that the new deal includes additional targets in “multiple therapeutic areas.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.